LiveCare, Inc. (LVCE) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.87: the stock has moved about 13% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerLiveCare, Inc. (LVCE) trades at $0.0058. LiveCare, Inc. (LVCE) is a healthcare technology company established in 2018, specializing in real-time health data analysis and remote patient monitoring for individuals with Type II diabetes. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for LVCE: LVCE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
LiveCare, Inc. (LVCE) Healthcare & Pipeline Overview
LiveCare, Inc. delivers technology-driven, human-centric solutions for real-time health data analysis and remote patient monitoring, primarily targeting Type II diabetes. Founded in 2018, the company operates within the evolving telehealth sector, focusing on improving health outcomes through personalized support services.
What Is the Investment Thesis for LVCE?
LiveCare, Inc. (LVCE) operates within the growing telehealth sector, focusing on the significant market opportunity presented by the Type II diabetic epidemic. The company's strategy of combining cutting-edge technology with a personalized, human-centric approach to real-time health data analysis and patient monitoring positions it to potentially capture a segment of the remote patient monitoring market. Key value drivers include the increasing demand for telehealth services and the continuous need for effective chronic disease management solutions. However, the company currently faces substantial financial challenges, evidenced by a profit margin of -288.3% and a gross margin of -229.1%, alongside a minimal market capitalization of $0.00B. Achieving profitability and scaling its operations from its current two-employee base are critical catalysts for future valuation. The company's listing on the OTC Other tier also introduces higher risk factors related to liquidity and disclosure. Investors would need to monitor LiveCare's ability to demonstrate a viable path to positive free cash flow, which currently stands at $-0.00B, and to expand its service offerings or market penetration to justify long-term growth.
Based on FMP financials and quantitative analysis
LVCE Key Highlights
Market Capitalization of $0.00B reflects a micro-cap valuation, indicating a very early-stage or thinly traded company.
- Profit Margin of -288.3% demonstrates significant unprofitability, suggesting high operational costs relative to revenue or minimal revenue generation.
- Gross Margin of -229.1% indicates that the cost of goods sold substantially exceeds revenue, pointing to fundamental challenges in its core business model's profitability.
- Free Cash Flow (FCF) of $-0.00B highlights negative cash generation from operations and investments, requiring external funding for sustenance.
- Beta of 0.87 suggests the stock is less volatile than the overall market, though this can be less indicative for thinly traded OTC securities.
Who Are LVCE's Competitors?
LVCE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| SCNX Scienture Holdings, Inc. | $3.97 | +2141.67% | $6.45M | — |
| ACON Aclarion, Inc. | $2.38 | -2.46% | $6.86M | — |
| MGRX Mangoceuticals, Inc. | $0.44 | -9.03% | $7.42M | — |
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.62 | -1.72% | $11.5M | — |
| BEAT HeartBeam, Inc. | $0.43 | +3.72% | $24.1M | — |
| ONMD OneMedNet Corporation | $5.39 | -2.00% | $30.7M | — |
| EUDA EUDA Health Holdings Limited | $17.24 | +8.33% | $32.2M | — |
| CCLD CareCloud, Inc. | $2.02 | -0.98% | $85.8M | 68 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LVCE's Key Strengths?
Specialized focus on Type II diabetes, addressing a significant and growing health challenge.
- Integration of cutting-edge technology with a personalized, human-centric approach.
- Operates in the high-demand telehealth and remote patient monitoring sector.
- Commitment to real-time health data analysis for proactive patient management.
What Are LVCE's Weaknesses?
Extremely small operational scale with only 2 employees, limiting capacity and reach.
- Significant unprofitability with -288.3% profit margin and -229.1% gross margin.
- Minimal market capitalization ($0.00B) indicating limited market presence and resources.
- Listing on the OTC Other tier, associated with higher risk and lower liquidity.
What Are the Key Risks for LVCE?
**Significant Unprofitability and Negative Margins:** The company's -288.3% profit margin and -229.1% gross margin indicate severe financial challenges, raising concerns about its long-term viability without substantial operational changes or capital infusion.
- **Limited Scale and Resources:** With only two employees and a minimal market capitalization, LiveCare, Inc. faces challenges in scaling operations, competing with larger entities, and sustaining growth.
- **OTC Other Tier Risks:** The listing on the OTC Other tier inherently carries risks of low liquidity, limited disclosure, and potential for price volatility, making it a high-risk investment.
- **Intense Competition in Telehealth:** The telehealth and remote patient monitoring market is highly competitive, with numerous established players and startups vying for market share, potentially hindering LiveCare's growth.
- **Regulatory and Compliance Challenges:** Operating in the healthcare sector, LiveCare is subject to complex and evolving regulatory requirements, including data privacy (e.g., HIPAA) and medical device approvals, which could pose significant compliance burdens.
What Threats Does LVCE Face?
- Intense competition from larger, more established healthcare technology companies.
- Regulatory compliance challenges within the evolving telehealth landscape.
- Difficulty in achieving profitability and scaling operations given current financial metrics.
- Negative perception and limited investor confidence associated with OTC Other tier listing.
What Are LVCE's Competitive Advantages?
- Specialized focus on Type II diabetes, potentially leading to deep expertise and tailored solutions.
- Integration of 'cutting-edge technological advancements' for real-time health data analysis.
- Emphasis on a 'personalized, human-centric approach' differentiating from purely tech-driven solutions.
- Proprietary algorithms or platforms for health data interpretation and patient monitoring.
- Early mover advantage or established presence in a niche segment of the telehealth market for diabetes.
What Does LVCE Do?
LiveCare, Inc., established in 2018 and headquartered in Venice, Florida, is a healthcare technology company dedicated to addressing the widespread diabetic epidemic and other chronic illnesses. The company's core mission involves integrating cutting-edge technological advancements with a personalized, human-centric approach to patient care. LiveCare specializes in several key areas: real-time health data analysis, comprehensive support services, and advanced patient monitoring systems. These solutions are primarily designed and delivered to individuals afflicted with Type II diabetes, a demographic facing significant challenges in managing their condition effectively. By focusing on this specific chronic illness, LiveCare aims to provide targeted interventions that can lead to improved health outcomes and enhanced quality of life for its users. The company's operational model emphasizes leveraging technology to provide continuous oversight and proactive support, moving beyond traditional episodic care. This involves collecting and analyzing health data in real time, allowing for timely adjustments to care plans and immediate responses to potential health issues. The human-centric aspect ensures that while technology forms the backbone, patient experience and individual needs remain at the forefront of its service delivery. LiveCare's strategic positioning within the telehealth sector allows it to contribute to the broader trend of remote healthcare delivery, making specialized care more accessible and efficient. With its headquarters in Venice, US, LiveCare, Inc. operates with a lean structure, employing two individuals to drive its mission in the healthcare information services industry.
What Products and Services Does LVCE Offer?
- Develops and implements cutting-edge technological advancements for healthcare.
- Provides real-time health data analysis for patient monitoring.
- Offers specialized support services for individuals with chronic illnesses.
- Focuses primarily on delivering targeted solutions for Type II diabetes management.
- Utilizes a personalized, human-centric approach in its patient care models.
- Operates within the telehealth sector, offering remote patient monitoring and virtual care.
- Aims to improve healthcare access and outcomes through technology.
How Does LVCE Make Money?
- Likely generates revenue through subscription fees for its real-time health data analysis and patient monitoring services.
- Potentially offers tiered service packages, providing varying levels of support and access to technological features.
- May partner with healthcare providers or insurance companies for service delivery and reimbursement.
- Focuses on a recurring revenue model based on continuous patient engagement and chronic disease management.
- Revenue generation is tied to the provision of specialized solutions for Type II diabetes and potentially other chronic illnesses.
What Industry Does LVCE Operate In?
LiveCare, Inc. operates within the Medical - Healthcare Information Services industry, a segment of the broader Healthcare sector that is experiencing significant transformation due to technological advancements and shifting patient expectations. The company's focus on telehealth and remote patient monitoring places it squarely within a rapidly expanding market driven by factors such as the aging global population, the rising prevalence of chronic diseases like Type II diabetes, and the increasing adoption of digital health solutions. The telehealth market, for instance, has seen accelerated growth, particularly in recent years, as healthcare providers seek more efficient and accessible ways to deliver care. LiveCare's specific niche in Type II diabetes management positions it within a competitive landscape that includes larger, established healthcare technology firms and numerous startups. Its differentiation lies in its stated commitment to a human-centric approach combined with real-time data analysis, aiming to carve out a specific identity in a crowded field where generic solutions often fall short. The industry trend favors integrated solutions that offer both technological sophistication and personalized patient engagement, which aligns with LiveCare's stated strategy.
Who Are LVCE's Key Customers?
- Individuals afflicted with Type II diabetes seeking advanced management solutions.
- Patients requiring real-time health data monitoring and personalized support for chronic conditions.
- Healthcare providers looking for remote patient monitoring tools to enhance patient care and outcomes.
- Caregivers and family members seeking reliable systems to support loved ones with chronic illnesses.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
LiveCare, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Venice, US. The company is led by CEO Cornelius Max Rockwell. LVCE has traded publicly since 2021.
LVCE Financials
LVCE Latest News
No recent news available for LVCE.
LVCE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LVCE.
Price Targets
Wall Street price target analysis for LVCE.
LVCE MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LVCE; grades run from A+ (80-100) to F (below 30).
Leadership: Cornelius Max Rockwell
Chief Executive Officer
Cornelius Max Rockwell is identified as the leader of LiveCare, Inc., managing its two employees. His leadership has focused the company on leveraging technological advancements and a human-centric approach to address chronic illnesses, particularly Type II diabetes, through real-time health data analysis and patient monitoring.
Track Record: Under Cornelius Max Rockwell's leadership, LiveCare, Inc. was founded in 2018 with a clear mission to tackle the diabetic epidemic. He has overseen the development of the company's core strategy, emphasizing cutting-edge technology and personalized support in remote patient monitoring. His tenure has been marked by the establishment of the company's headquarters in Venice, Florida, and its focused commitment to individuals afflicted with Type II diabetes within the telehealth sector.
LVCE OTC Market Information
LiveCare, Inc. is listed on the 'OTC Other' tier, which represents the lowest tier of the OTC Markets Group's three marketplaces (OTCQX, OTCQB, and OTC Pink). Companies on the OTC Other tier are typically micro-cap, distressed, or shell companies that do not meet the minimum disclosure standards of OTCQX or OTCQB. Unlike companies on major exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and public disclosure, OTC Other companies have minimal or no public disclosure requirements, leading to significantly less transparency for investors.
- OTC Tier: OTC Other
- **Limited Disclosure and Transparency:** The 'Unknown' disclosure status means investors have little to no access to current financial statements, operational updates, or other material information, making informed investment decisions exceptionally difficult.
- **Extremely Low Liquidity:** A $0.00B market cap and OTC Other listing indicate very few shares traded, leading to wide bid-ask spreads and significant challenges in buying or selling shares without impacting the price.
- **Higher Volatility and Price Manipulation Risk:** Stocks on the OTC Other tier are often more susceptible to extreme price fluctuations and potential manipulation due to limited oversight and low trading volume.
- **Difficulty in Valuation:** The absence of comprehensive financial data and analyst coverage makes traditional valuation methods nearly impossible, forcing investors to rely on limited and potentially outdated information.
- **Limited Access to Capital:** Companies on the OTC Other tier often struggle to raise capital from institutional investors due to their high-risk profile and lack of transparency, which can hinder growth and operational stability.
- Verify the company's current operational status and any recent business developments through independent sources, if available.
- Attempt to locate any publicly filed financial statements or disclosures, even if not formally required by the OTC Markets Group.
- Research the background and track record of Cornelius Max Rockwell and any other key personnel beyond what is provided.
- Assess the actual market for LiveCare's products/services, including customer acquisition and retention, if any data can be found.
- Investigate any potential regulatory actions or compliance issues, especially given the 'Unknown' disclosure status.
- Understand the company's capital structure and any outstanding debt or equity financing that may not be publicly disclosed.
- Evaluate the long-term viability of the business model given the reported negative profit and gross margins.
- The company was established in 2018, indicating a foundational history of several years.
- It has a stated headquarters in Venice, US, suggesting a physical operational base.
- A specific business description focusing on Type II diabetes and chronic illnesses provides a clear mission.
- Identification of a CEO, Cornelius Max Rockwell, provides a known individual at the helm.
- The company operates in a legitimate and growing sector (Healthcare, Telehealth).
LVCE Healthcare Stock FAQ
What are the key financial challenges facing LiveCare, Inc.?
LiveCare, Inc. is currently facing significant financial challenges, as indicated by its reported metrics. The company has a profit margin of -288.3% and a gross margin of -229.1%, suggesting that its operational costs and the cost of delivering its services far exceed its revenue.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial and operational data provided, especially regarding revenue, specific product details, and market penetration.
- Inferred business model details based on general industry practices for remote patient monitoring and support services.
- CEO background and track record are based on company founding date and stated mission due to lack of specific biographical data.
- Market cap of $0.00B is taken literally from source, implying extremely low or untracked valuation.